In focus · trending topic

Intellia Therapeutics

1 stories · following the connections

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

By Nasdaq OMXDec 16, 2016, 1:00 PM UTC